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Abstract
Background: Intrahepatic hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is the original template
for HBV replication. The persistence of cccDNA is responsible for the recurrence of HBV infection. The detection of
cccDNA can help the development of new antiviral drugs against HBV replication links, and reduce the resistance
and recurrence as well as to discover extrahepatic HBV infection. In situ polymerase chain reaction (IS-PCR) can be
used to determine the distribution and localization of cccDNA in liver tissues, but it is hampered by its low
sensitivity and specificity. We developed a novel method to detect HBV cccDNA using rolling circle amplification
(RCA) combined with IS-PCR.
Methods: Biopsy liver tissues were obtained from 26 patients with HBV infection, including 10 chronic hepatitis B
(CHB), 6 liver cirrhosis (LC) and 10 hepatocellular carcinoma (HCC) patients. Four pairs of primers were designed to
mediating RCA for the first round amplification of HBV cccDNA specifically. The liver tissue sections from patients were
treated by plasmid-safe ATP-dependent DNase (PSAD) prior to RCA. After RCA, HBV cccDNA was further amplified by a
pair of selective primers labeled digoxigenin that target the gap region between the two direct repeat regions (DR1
and DR2) of the virus via IS-PCR.
Results: HBVcccDNA was expressed and located in hepatocyte nucleus in 19 patients (73.07%). Compared with the IS-PCR,
the introduction of RCA increase the limit of detection. RCA combined with IS-PCR yielded strong positive signals in HCC
liver tissue in spite of low copy number cccDNA (2 copies of target sequence per cell), meanwhile, no positive signal was
detected via negative control.
Conclusions: RCA combined with IS-PCR is an effective and practicable method which could detect the presence of low
copy number of cccDNA sensitively and specifically, and reflect the relationship between cccDNA expression level and liver
tissue pathological characteristics.
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Background
Chronic hepatitis B virus (HBV) infection remains a ser-
ious health problem that currently affects over 350 mil-
lion people in the world and 93 million people in China
[1-3]. It is estimated that 500 000 to 1 000 000 people
die each year from HBV-related liver disease, such as
liver cirrhosis (LC), hepatic decompensation, and hepa-
tocellular carcinoma (HCC) [4]. Treatment of chronic
hepatitis B (CHB) is aimed at suppressing viral replica-
tion to the lowest possible level, and thereby to halt the
progression of liver disease and prevent the onset of
complications [5]. However, it has always been ham-
pered by the high relapse rate after discontinuation of
the treatment. One crucial step within the HBV life cycle
is the formation of covalently closed circular DNA
(cccDNA), which serves as original template for viral
replication with approximately 5–50 cccDNA molecules
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per infected hepatocyte [6]. Intrahepatic HBV cccDNA is
responsible for the persistence of the disease in hepato-
cytes and it has been a key indicator to evaluate anti-
HBV therapeutic efficacy [7,8]. In addition, the HBV
cccDNA level is considered to be valuable for studying
HBV recurrence after liver transplantation and extrahe-
patic HBV infection [9,10].
The development of highly selective real-time poly-
merase chain reaction (PCR) assays has provided sensi-
tive tools to investigate the replicate activity and the
effectiveness of antiviral therapy in infected patients by
detection and quantification of the cccDNA in human
liver biopsies [11-13]. However, the problem of nonspe-
cific amplification of relaxed circular DNA (rcDNA) is a
major obstacle in the development of an accurate
cccDNA quantification assay. In a previous study, we
improved and developed a quantification by introducing
rolling circle amplification (RCA) steps combined with
plasmid-safe ATP-dependent DNase (PSAD) digestion
and real-time PCR, which offered better resolution [14].
However, these quantitative analysis methods could not
reveal the distribution and localization of HBV cccDNA
in liver tissues and further analyze the relationship be-
tween cccDNA and pathological characteristics.
Therefore, we developed a new sensitive and specific
method for the locating detection of HBVcccDNA in
sections from formalin fixed paraffin-embedded (FFPE)
liver tissues by using RCA combined with in situ poly-
merase chain reaction (IS-PCR).
Methods
Ethics statement
This study was approved by the ethics committee of
Beijing 302 Hospital. In this study, all samples were the
residuary tissues of pathological examination, limited to
in vitro studies, and didn’t have any contact and harm to
patients, the institutional review board has waived the
need for written informed consent from the participants.
Study subjects
FFPE liver biopsy tissues (from the residuary tissues of
pathological examination) were obtained from 26 HBV in-
fected patients (21 male, 5 female; median age 39.73 years),
hospitalized in Beijing 302 Hospital during a period from
July 2011 - July 2012. According to the imaging and histo-
logical examination of liver, the patients were grouped into
10 CHB patients, 6 LC patients and 10 HCC patients. The
characteristics of the patients are shown in Table 1. None
of the patients received anti-HBV agents or steroids within
six months prior to sampling. Concurrence of HCV, HDV,
HIV infection, autoimmune liver disease and alcoholic
liver disease was excluded for all enrolled individuals.
FFPE liver biopsy tissues from four subjects without HBV
infection (including two patients with HCV, one liver
transplant from a healthy donor) and one of mice which
transgenic complete HBV genomes) were collected as
negative control.
Serological markers and quantification of HBV DNA and
cccDNA
Serum ALT, HBeAg/anti-HBe and other serological markers
were routinely measured or detected in the Central Clinical
Laboratory of the Beijing 302 Hospital. Serum HBV DNA
level was determined by real -time quantitative PCR kit
(Fosun Pharmaceutical Co., Ltd., Shanghai, China) with a
lower detection limit of 100 IU/ml (≈500 copies/ml). Quan-
tification of intrahepatic HBV cccDNA using rolling circle
amplification in combination with real-time PCR according
to the literature [14]. Intrahepatic HBV cccDNA levels were
normalized by the amount of human genomic (hg)-beta-
actin in the samples. Cell numbers were calculated based on
an estimation of 6.667 pg/hgDNA per cell.
Sample preparation
The liver tissue samples were fixed in 10% buffered forma-
lin (pH 7.4) for 24 hrs, embedded in paraffin, cut into
5μm sections, and mounted on 0.05% poly-L-Lysine glass
slides, followed by incubation at 60°C for 2 hrs. Tissue
sections (5μm) were first stained with hematoxylin and
eosin (HE) and studied to confirm the adequacy of the
biopsy.
Deparaffinization and digestion
The sections were deparaffinized with two pre-warmed xy-
lene washes followed by 95%, 75%, and 50% ethanol rinses.
The sample slides were dried at room temperature after
washing in distilled water. After deparaffinizing by the nor-
mal method, the tissue sections on the glass slides were
digested with proteinase K (Boster Biotech, Wuhan, China)
50 μg/ml at 37°C for 10 min in a humidified chamber and
then the sections were rinsed with phosphate-buffer saline
(PBS). PSAD (Epicentre, Madison, Wisconsin, USA) was
used to digest HBV rcDNA, replicate double-stranded
DNA (dsDNA) and single-stranded DNA (ssDNA). The re-
action mixture contained 3U PSAD, 1.0 mmol/l ATP and
1 μl 10 × reaction buffers, with doubly distilled water
(ddH2O) to final volume of 15.5 μl. The digestion was car-
ried out at 37°C for 30 min and inactivated at 70°C for
30 min. Endogenous alkaline phosphatase (AP) in the liver
tissues was removed byusing 20% acetic acid (in order to
increase the permeability of cell membrane) for 10 min at
room temperature. Subsequently, the sections were fixed in
4% formaldehydum polymerisatum, rinsed with distilled
water, dehydrated by 75% ethanol, 95% ethanol and 100%
ethanol, and air dried.
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Table 1 Patient profiles and results of the present study
Patient No. Age (year) Gender Serum ALT (IU/L) HBs Ag HBe Ag Serum HBV DNA (IU/mL) PSAD + RCA + IS-PCR detect HBVcccDNA Note
CHB
1 0-10 M 89 + + 1.33 × 107 + Figure 2
2 21-30 M 68 + + 1.46 × 102 +
3 21-30 M 22 + + 3.595 × 102 +
4 21-30 M 197 + - 7.51 × 104 +
5 11-20 M 21 + + 3.54 × 108 +
6 11-20 M 13 + + 1.51 × 103 -
7 50-60 M 45 + - 1.2 × 105 -
8 50-60 M 263 + + 2.73 × 105 +
9 20-30 F 54 + - 3.03 × 104 -
10 20-30 F 381 + + 4.75 × 107 +
LC
1 40-50 M 20 + - 5.13 × 107 + Figure 3
2 40-50 M 58 + - 1.509 × 104 +
3 40-50 M 33 + - 1.17 × 103 +
4 50-60 M 25 + + 4.542 × 103 +
5 50-60 M 136 + - 3.08 × 102 -
6 40-50 F 44 + + U.D. -
HCC
1 30-40 M 55 + - U.D. + Figure 4
2 40-50 M 47 + - U.D. +
3 40-50 M 12 + - 2.829 × 102 -
4 40-50 M 44 + - 2.446 × 106 +
5 50-60 F 25 + + 2.182 × 104 +
6 50-60 M 14 + - 1.11 × 103 +
7 60-70 M 88 + + 1.79 × 103 +
8 60-70 M 17 - - U.D. +
9 40-50 F 35 + - 4.464 × 103 -
10 30-40 M 206 + - 4.44 × 10 +
M, male; F, female; U.D., undetected; HBV, hepatitis B virus; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; PSAD, plasmid-safe ATP-dependent DNase; RCA, rolling circle




















Four pairs of primers were designed for mediating RCA
for the first amplification round of HBV cccDNA specific-
ally (Table 2). In order to increase the efficiency of amplifi-
cation, RCA was divided into two steps: First-step, 14 μl
primer combining reaction mixture containing primers at
a operative solutionconcentration of 0.5 μmol/l each , 2 μl
reaction buffer and 11 μl ddH2O were loaded onto the tis-
sue sections on glass slides and sealed with rubber ce-
ment, followed by heating at 95°C for 6 min, and then
placed on ice for 15 min. Second-step the RCA amplifica-
tion was as follows: 23 μl of reaction mixture was added
to tissue slides containing primers at a operative solution
concentration of 0.5 μmol/l each, 10 mg/ml bovine serum
albumin (BSA), 0.32 mmol/l of dNTP, 20 U of the Phi29
DNA polymerase (New England Biolabs, Worcester, MA),
and 2 μl reaction buffer. Reaction was carried out over-
night for 16 hrs at 30°C. Then Phi29 DNA polymerase
was inactivated at 70°C for10 min. Subsequently, the sec-
tions were fixed in 4% formaldehydum polymerisatum,
rinsed with distilled water, dehydrated in a graded series
of alcohol and air dried.
IS-PCR and immunohistochemical staining for
detecting HBV cccDNA
HBV cccDNA was further amplified with IS-PCR medi-
ated by a pair of cccDNA-selective primers labeled with
digoxigenin at 5′-terminal, that targets the gap region be-
tween the two direct repeat regions (DR1 and DR2) of the
viral genome (Table 2) [14]. 23.5 μl reaction solution con-
taining a operative solutionconcentration of 0.32 mmol/L
dNTP, 10 mg/ml BSA, 3.5 μmol/l MgCl2, 5 μl of Taq poly-
merase PCR buffer, 5 μl of ddH2O, 0.2 μmol/l of selective
primers, and 10 U Taq polymerase (TaKaRa Biotechnol-
ogy, Dalian, China) was added to the tissue slides and
sealed with rubber cement. The slides were encapsulated
with silver paper and placed in the thermal cycle system
(ThermoPX2, USA) at 95°C for 3 min followed by 30 cy-
cles of 95°C for 1 min, 55°C for 90 s, 72°C for 90 s and a
final extension at 72°C for 10 min. Immediately after the
PCR, the slides were fixed in 4% paraformaldehyde for
10 min, washed in Tris–HCl buffer saline (TBS) for 3 min,
rinsed with distilled water for 3 min, dehydrated in a
graded series of alcohol and air dried.
After IS-PCR, sample slides were washed with 0.1% Tri-
ton X-100 in Tris–HCl buffer saline (TBS-T) for 10 min
and TBS for 3 min at room temperature. After incubated
in blocking reagent 3% BSA at 37°C temperature for
10 min, the slides were covered with 100 μl Alkaline phos-
phatase, conjugated Monoclonal Anti-Digoxin (SIGMA,
Saint Louis, Missouri, USA) and 1 than 30 dilution with
TBS at 37°C for 120 min. After this reaction, the slides
were washed twice (3 min each) with TBS. The slides were
incubated in 30 μl dye solution (338 μg/ml nitroblue tetra-
zolium chloride NBT, 175 μg/ml 5-bromo-4-chloro-3-
indolyl-phosphate 4-toluidine salt BCIP) at 37°C in the
dark. After sufficient color development, they were
washed with de-ionized water for three times and then
nuclear fast red re-stained. Finally, the slides were sealed
by using neutral balsam for microscopic examination.
Evaluation of sensitivity, repeatability and specificity of
the assay
To evaluate this method’s sensitivity, we chose a liver tis-
sue with low copy number (2 copies cccDNA per cell)
from a HCC patient as template, which the quantification
of intrahepatic HBV cccDNA according to our previous
study [14]. The repeatability was evaluated by detecting
the serial sections which were cut from same sample in
inter-assay and intra-assay. Intra-assay reproducibility was
assessed by repeating cccDNA detection of FFPE liver bi-
opsy samples selected from three patients randomly from
Table 2 Oligonucleotide sequences of primers used in this study
Name Sequence (5′→ 3′) Nucleotide position Polarity
Primers for rolling circle amplification (RCA)
RCA1 AATCCTCACAATA*C*C 226-240 Sense
RCA2 ACCTATTCTCCTC*C*C 1744-1758 Antisense
RCA3 CCTATGGGAGTGG*G*C 637-651 Sense
RCA4 CCTTTGTCCAAGG*G*C 2675-2689 Antisense
RCA5 ATGCAACTTTTTC*A*C 1814-1828 Sense
RCA6 CTAGCAGAGCTTG*G*T 15-29 Antisense
RCA7 TAGAAGAAGAACT*C*C 2368-2382 Sense
RCA8 GGGCCCACATATT*G*T 2585-2599 Antisense
Primers for in situ PCR (IS-PCR)
Pup58 CCCCGTCTGTGCCTTCTC 1547- 1564 Sense
Pdown84 CAGCTTGGAGGCTTGAACAGT 1859-1879 Antisense
*Indicates primer phosphorothioate modifications so as to prevent degradation by nucleases.
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CHB、LC、HCC respectively for three times in a single
run. Inter-assay variation was evaluated by detecting the three
patients’ samples mentioned above in three independent ex-
periments. The specificity was assessed by examining FFPE
liver biopsy tissue taken from the patients with HCV, from
healthy adults and from transgenic mice. In addition, FFPE
liver biopsy tissue from the patient with HCC, which were
amplified in situ omitting specific primer, labled primers,
phi29 polymerase and Taq DNA polymerase respectively, in-
stead of ddH2O, were also examined for evaluation of the
specificity of the assay.
Methodological comparison
Liver tissues from patients with CHB and HBV-related
LC, HCC were detected using three different methods as
follows:
1) Amplification of samples by IS-PCR (IS-PCR).
2) Treatment of samples with PSAD by IS-PCR (PSAD
+ IS-PCR).
3) Treatment of samples with PSAD followed by RCA
prior to IS-PCR (PSAD + RCA + IS-PCR).
Nucleotide sequence accession numbers
The sequences accession numbers of the HBV genomes




19 of 26 (73.07%) samples from HBV-infected patients in-
cluding 7 of 10 CHB, 4 of 6 LC and 8 of 10 HCC were
found positive for cccDNA by in situ amplification using
PSAD+RCA+ IS-PCR (Table 1). Liver cells with positive
staining were scattered in tissues with clustering, and the
signals compartment in the nuclear, staining blue or blue-
violet. Interestingly, strong positive signals could be ob-
served in the liver tissue from the patients with HCC despite
of low copy number cccDNA. The detection threshold is 2
copies of target sequence per cell.
Intra-assay and inter-assay variability experiments
The positive expression intensity and distribution of
replicate test were essentially consistent. Repeated ex-
periments showed that this method shows good stability
and reproducibility.
Control study
The specificity of PSAD + RCA + IS-PCR method was
examined in a serious of control experiments. No posi-
tive signals were detected when the primers, phi29 poly-
merase or Taq DNA polymerase were omitted, neither
in the liver specimens from the patients with HCV,
healthy adults and transgenic mice (Figure 1).
Figure 1 IS-PCR and immunohistochemical staining for detecting HBV cccDNA in FFPE liver biopsies. No positive signal was detected in
liver tissue samples from HCV patient (a), healthy adults (b), transgenic mice (c) and HCC patients without specific primers (d) by PSAD + RCA +
IS-PCR. Original Magnifications × 200.
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Methodological comparison
Compared with IS-PCR methods, PSAD+ RCA + IS-PCR
increased the sensitivity and specificity of HBV cccDNA
detection. HBVcccDNA were detected in the liver tissues
from patients with CHB (Figure 2), LC (Figure 3) and
HCC (Figure 4) by PSAD+ RCA + IS-PCR, whereas no
positive signal was detected in the consecutive tissue sec-
tions that were subjected to IS-PCR and PSAD+ IS-PCR.
Discussion
HBV cccDNA plays a key role in the life cycle of the
HBV and permits the persistence of infection. Studies
have reported a development or improvement in the
methodology to quantify viral cccDNA more specifically
and sensitively [11,15-17]. Using this method, we devel-
oped a quantification of HBVcccDNA in FFPE liver tis-
sue using RCA combined with real-time PCR and
examined 130 samples from the patients with CHB in
our previous studies [14]. In order to observe distribu-
tion and localization of HBV cccDNA in liver tissues
and further analyze the relationship between cccDNA
and pathological characteristics, we developed a highly
specific and sensitive method to detect the HBV
cccDNA in liver tissues via RCA combined with IS-PCR.
RCA is a novel isothermal DNA amplification method
with an amplification mechanism quite different from
conventional PCR. This method uses a specially designed
circular probe (C-probe) in which the 3′ and 5′ ends are
brought together in juxtaposition by hybridization to a tar-
get. The two ends are then covalently linked by a T4 DNA
ligase in a target-dependent manner, producing a closed
DNA circle. In the presence of an excess of primers (for-
ward and reverse primers), a DNA polymerase extends
the bound forward primer along the C-probe and
displaces the downstream strand, generating a multimeric
single-stranded DNA (ssDNA), analogous to the “rolling
circle” replication of bacteriophages in vivo. This multi-
meric ssDNA then serves as a template for multiple reverse
primers to hybridize, extend, and displace downstream
DNA, generating a large ramified (branching) DNA com-
plex. This ramification process continues until all ssDNAs
become double-stranded, resulting in an exponential ampli-
fication that distinguishes itself from the previously de-
scribed nonexponential rolling circle amplification [18].
The major advantage of RCA is its efficiency and fidelity. It
exhibits less amplification bias and greater yield, product
length, and fidelity than conventional PCR [19]. In 2008,
Margeridon et al. [20] first applied RCA for qualitatively
probing HBV cccDNA. We also applied RCA to analyze
drug resistant mutations of HBV cccDNA in patients with
chronic hepatitis B [21]. RCA relies on the properties of the
phi29 DNA polymerase that possesses a strong 3 exonucle-
ase (proofreading) activity, is able to polymerize more than
70,000 nucleotides without detaching from the template,
and that can displace previously elongated strands [20].
Phi29 DNA polymerase used in RCA can selectively amp-
lify circular template molecule [22], it minimizes the impact
of integrated HBV DNA and obviously improves the sensi-
tivity and specificity of HBV cccDNA assay. In the present
study, a more efficient amplification was operated by add-
ing 4 pairs of RCA primers targeting multiple binding sites.
Therefore, RCA were optimized to improve their sensitivity
without impairing the specificity.
IS-PCR, which is the combination of PCR and ISH,
was first described by Haase et al. in 1990 [23]. IS-PCR
has the advantages of both PCR and ISH. It has been
adapted to in situ amplification of viral genomes or their
replicate intermediates in liver tissue sections [24,25]
and can localize a single gene copy at the individual cell
level [26-28]. But the sensitivity and specificity remain
major challenges to the application.
In practice, IS-PCR is technically difficult, especially
when using paraffin-embedded tissue sections, because
there is no standard protocol for optimal detection. In
fact, in this method the diffusion of the amplified products
from the target cells is a major problem. The factors that
influence diffusion include excessive protease digestion
[26,29] and the use of an excessive number of PCR
Figure 2 IS-PCR and immunohistochemical and HE staining for detecting HBV cccDNA in FFPE liver biopsies of CHB patient.
HBVcccDNA were detected in the liver tissues by PSAD + RCA + IS-PCR (c), whereas no positive signal was detected in the tissue sections that
were subjected to IS-PCR (a) and PSAD + IS-PCR (b). (d) hematoxylin-eosin staining of FFPE liver biopsies of CHB patient. The arrow in the images
shows HBVcccDNA positive signals in the hepatocyte nuclei. Original magnifications ×400.
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amplification cycles [30,31]. The key step in the IS-PCR is a
controlled proteinase K pretreatment. Optimal proteinase
treatment permeates sections sufficiently to permit entry of
PCR reagents into cells without leakage of the PCR products
or loss of tissue morphology. So, the concentration of pro-
teinase K and the treatment time were adjusted to optimize
permeability of membranes and the release of protein-
nucleic acid cross-linking, while avoiding over digestivity. To
minimize diffusion of the PCR products, we chose the opti-
mal proteinase K concentration (50 μg/ml for paraffin sec-
tions) for 10 min, which produced a positive sharp in situ
PCR signal. We also limited the number of PCR cycles,
which was important for eliminating the background stain-
ing, as too many cycles resulted in high background staining
and loss of tissue morphology. Finally, we fixed the liver tis-
sue sections in 4% paraformaldehyde immediately after PCR
amplification: this step is essential to avoid diffusion of PCR
products into neighboring cells.
In this study, First of all, we used PSAD to digest
linearization of the rcDNA. PSAD pretreatment proved to
be necessary, without this step, there was an obvious in-
crease of amplicons amount, which was reasonably coming
from the nonspecific amplification. But the impact of inte-
grated HBV DNA could not be excluded. To solve this
problem, RCA in situ optimally performed at 30°C for
16 hrs. It can minimize the impact of integrated HBV DNA
and obviously improve the specificity of HBV cccDNA
assay. Finally, the slides were placed in an IS-PCR system
and amplification reaction was performed as described in
materials and methods. By means of this method, we ob-
tained clear and reproducible patterns of distribution or
localization of the HBV cccDNA in the liver tissue sections.
Our results showed that HBV cccDNA were detected in a
large number of hepatocytes in tissue sections from HBV-
infected patients. Positive signals were observed in the nu-
cleus despite of low copy number cccDNA (2 copies of tar-
get sequence per cell). These data indicate that the method
is specific and sensitive for the detection of HBV cccDNA.
Conclusions
RCA combined with IS-PCR could sensitively and specif-
ically detect HBV cccDNA in infected hepatocytes, and
visualize the tissue staining patterns. Distribution and
localization of HBV cccDNA in liver tissues could be
made visible to the unaided eye under a light microscope,
which can reflect the relationship between cccDNA ex-
pression level and liver tissue pathological characteristics
so as to evaluate anti-HBV therapeutic efficacy. Our assay
also may provide a powerful tool for discovering the exist-
ence of extrahepatic cccDNA.
Figure 4 IS-PCR and immunohistochemical and HE staining for detecting HBV cccDNA in FFPE liver biopsies of HCC patient.
HBVcccDNA were detected in the liver tissues by PSAD + RCA + IS-PCR (c), whereas no positive signal was detected in the tissue sections that
were subjected to IS-PCR (a) and PSAD + IS-PCR (b). (d) hematoxylin-eosin staining of FFPE liver biopsies of HCC patient. The arrow in the images
shows HBVcccDNA positive signals in the hepatocyte nuclei. Original magnifications ×400.
Figure 3 IS-PCR and immunohistochemical and HE staining for detecting HBV cccDNA in FFPE liver biopsies of LC patient. HBV cccDNA
were detected in the liver tissues by PSAD + RCA + IS-PCR (c), whereas no positive signal was detected in the tissue sections that were subjected
to IS-PCR (a) and PSAD + IS-PCR (b). (d) hematoxylin-eosin staining of FFPE liver biopsies of LC patient. The arrow in the images shows
HBVcccDNA positive signals in the hepatocyte nuclei. Original magnifications ×400.
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